We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $64 million initial public offering by Molecular Partners AG of 3,000,000 American depositary shares, each representing one common share. The ADSs are listed on the Nasdaq Global Select Market under the symbol “MOLN.”

Headquartered in Schlieren, Switzerland, Molecular Partners is a clinical stage biopharmaceutical company applying its pioneering DARPin product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Gil Savir and Taeo I. Carse. Partner David R. Bauer and associates Jesse L. Hallock and Marisa Elena Bannon provided intellectual property advice. Partner Mario J. Verdolini provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post